{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:13:19Z","timestamp":1789870399662,"version":"4.0.1"},"reference-count":55,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T00:00:00Z","timestamp":1368489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Abdominal aortic aneurysm (AAA) is a condition that mainly affects elderly men. At present, there is no effective medical therapy that can retard aneurysm growth or prevent aneurysm rupture. There is evidence that angiogenesis within the wall of an aortic aneurysm may play key roles in aneurysm progression as well as rupture. The use of anti\u2010angiogenic therapy as potential medical therapy in AAA is a promising strategy but has never been studied in detail.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>This paper discusses the basic mechanisms of angiogenesis, the role played by angiogenesis in aortic aneurysms and the potential therapeutic role of anti\u2010angiogenic drugs against aneurysm expansion or rupture.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Angiogenesis is a multi\u2010step process which is fundamental for growth and differentiation of various tissues within a multi\u2010cellular organism. Hypoxia and inflammation are key stimuli for activation of neoangiogenesis. Investigations in both human tissues and animal models of AAA have shown that angiogenesis is a pathological hallmark of AAA and appears to play a role in the development and progression of the condition. Pre\u2010clinical studies have shown that anti\u2010angiogenic drugs can potentially be effective in reducing the intensity of aneurysm formation, suggesting that such drugs may potentially be useful as novel drug therapy for AAA in humans.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Current evidence suggests that angiogenesis contributes to the destructive processes within aneurysmal aortic wall. As novel drug therapy for aortic aneurysms (for use in humans) is still eluding researchers, anti\u2010angiogenic pathway appears to be an attractive approach.<\/jats:p><\/jats:sec>","DOI":"10.1111\/eci.12103","type":"journal-article","created":{"date-parts":[[2013,4,3]],"date-time":"2013-04-03T19:29:22Z","timestamp":1365017362000},"page":"758-765","source":"Crossref","is-referenced-by-count":34,"title":["Potential role for anti\u2010angiogenic therapy in abdominal aortic aneurysms"],"prefix":"10.1111","volume":"43","author":[{"given":"Badri","family":"Vijaynagar","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Sciences University of Leicester Leicester UK"},{"name":"Department of Vascular Surgery Leicester Royal Infirmary Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt J.","family":"Bown","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences University of Leicester Leicester UK"},{"name":"Department of Vascular Surgery Leicester Royal Infirmary Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Sayers","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences University of Leicester Leicester UK"},{"name":"Department of Vascular Surgery Leicester Royal Infirmary Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Choke","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences University of Leicester Leicester UK"},{"name":"Department of Vascular Surgery Leicester Royal Infirmary Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,5,14]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"CD002945","article-title":"Screening for abdominal aortic aneurysm","author":"Cosford PA","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2168.2002.02122.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.5778"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvp155"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2174\/157016111796197288"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1999.tb07682.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1128\/CDLI.6.6.891-894.1999","article-title":"Can an antibiotic (macrolide) prevent Chlamydia pneumoniae\u2010 induced atherosclerosis in a rabbit model?","volume":"6","author":"Fong IW","year":"1999","journal-title":"Clin Diagn Lab Immunol"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1067\/mva.2001.117891"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2010.08.023"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2008.12.048"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1538574408315205"},{"key":"e_1_2_9_13_1","first-page":"52","article-title":"Impaired results of a randomised double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms","volume":"18","author":"Lindholt JS","year":"1999","journal-title":"Int Angiol"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0007-1323.2001.01845.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1067\/mva.2002.121308"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.avsg.2006.10.008"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1383.007"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/386671a0"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(00)00281-9"},{"key":"e_1_2_9_20_1","first-page":"444","article-title":"Vascular endothelial growth factor (VEGF) \u2010 part 1: in physiology and pathophysiology","volume":"62","author":"Kajdaniuk D","year":"2011","journal-title":"Endokrynol Pol"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0603-653"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.20.4.409"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1006\/jsre.2002.6468"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1078-5884(96)80183-3"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2010.02.015"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(05)80007-2"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000234944.22509.f9"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2004.67"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.213157"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1383.005"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1067\/mva.2001.114813"},{"key":"e_1_2_9_32_1","first-page":"1507","article-title":"Media conditioned by smooth muscle cells cultured in a variety of hypoxic environments stimulates in vitro angiogenesis. A relationship to transforming growth factor\u2010beta 1. The","volume":"141","author":"Sakuda H","year":"1992","journal-title":"Am J Pathol"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004320050312"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.6612342"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.69.1490"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/13684730310001652"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-821X(05)80118-5"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2006.11.020"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(97)70210-6"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.09.6"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1381"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04483"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.14.1.1"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/362841a0"},{"key":"e_1_2_9_45_1","first-page":"609","article-title":"Safety and efficacy of bevacizumab combined with taxanes in the first\u2010line treatment of metastatic breast cancer: ATHENA study\u2010France","volume":"99","author":"Hardy\u2010Bessard AC","year":"2012","journal-title":"Bull Cancer"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvr080"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302496"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.111.230201"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.111.235002"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2005.10.015"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.109.192609"},{"key":"e_1_2_9_52_1","article-title":"Statins: The Holy Grail of Abdominal Aortic Aneurysm (AAA) Growth Attenuation? A systematic review of the literature","author":"Dunne JA","year":"2012","journal-title":"Curr Vasc Pharmacol"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2011.07.041"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.108.173682"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2009.02.001"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000085631.76095.64"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Feci.12103","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/eci.12103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T10:51:23Z","timestamp":1700650283000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/eci.12103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,14]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1111\/eci.12103"],"URL":"https:\/\/doi.org\/10.1111\/eci.12103","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,14]]}}}